Skip to main content
VCbacked
Log inGet Started

Allorion Therapeutics

Natick, United States

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.

$50.0M raised
Mar 2023
Series B
MedicalPharmaceuticalTherapeutics

Top Investors

Qiming Venture PartnersINCE CapitalIDG CapitalOctagon Capital AdvisorsMed-Fine Capital

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Allorion Therapeutics

How much funding has Allorion Therapeutics raised?
Allorion Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in March 2023.
Who are Allorion Therapeutics's investors?
Allorion Therapeutics's investors include Qiming Venture Partners, INCE Capital, IDG Capital, Octagon Capital Advisors, Med-Fine Capital.
Where is Allorion Therapeutics headquartered?
Allorion Therapeutics is headquartered in Natick, United States.
What does Allorion Therapeutics do?
Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses.
What stage is Allorion Therapeutics at?
Allorion Therapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Allorion Therapeutics — Funding & Investors." VCBacked, March 9, 2023, https://www.vcbacked.co/company/allorion-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2023). Allorion Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/allorion-therapeutics
Wikipedia (cite web)
{{cite web |title=Allorion Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/allorion-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Medical

View all
Tempus
Chicago
Sedivention
Munich$848K
Anagram Therapeutics
Boston
ParcelBio
San Francisco$13.2M
LTZ Therapeutics
San Francisco$40.0M
Autoimmunity BioSolutions
Houston$2.0M